Trial design. The trial consisted of 5 visits. At Visit 2, patients were dosed with their previous FIX product and blood samples for pharmacokinetic assessments were taken at the time points (in hours) indicated below the arrows. At Visit 3, patients were dosed with N9-GP and blood samples for safety and pharmacokinetic assessments were taken at the time points (in hours) indicated below the arrows. There was a wash-out period of at least 7 days before Visits 2, 3, and 5.